Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Longboard Pharmaceuticals, Inc. Frequently Asked Questions
What is the ticker symbol for Longboard Pharmaceuticals, Inc.? What does LBPH stand for in stocks?
LBPH is the stock ticker symbol of Longboard Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Longboard Pharmaceuticals, Inc. (LBPH)?
As of Fri Nov 29 2024, market cap of Longboard Pharmaceuticals, Inc. is 2.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of LBPH stock?
You can check LBPH's fair value in chart for subscribers.
Is Longboard Pharmaceuticals, Inc. a good stock to buy?
The fair value guage provides a quick view whether LBPH is over valued or under valued. Whether Longboard Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Longboard Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LBPH.